Sunshine Biopharma Closes $6M Unit Offering — 43.6M Warrant Shares Loom Over 4.3M Outstanding
SBFM is trading near its 52-week low of $0.331 (1.3% below the low).
Summary
A $6M unit offering at $0.55/unit with Series D Warrants that could add up to 43.6M shares — over 10x current outstanding — has been closed by Sunshine Biopharma. The deal includes a reverse-split-triggered exercise price reset to as low as $0.275.
Key Events · Financing and Capital Events · SBFM
-
$6M Unit Offering Closed
The offering closed on October 9, 2026 with gross proceeds of ~$6M. It comprised 10,509,082 Common Units at $0.55 each (one share plus two Series D Warrants) plus 400,000 Pre-Funded Units at $0.54999.
-
Massive Warrant Overhang
There are 21,818,164 Series D Warrants exercisable at $0.66 for five years, plus 400,000 Pre-Funded Warrants at $0.00001. If fully exercised, up to 43.6M new shares would be issued — over 10x the 4.3M currently outstanding.
-
Reverse-Split Price Reset Risk
The Series D Warrants include a Share Combination Event provision: if a reverse split occurs and the VWAP falls below the exercise price, the strike drops to as low as $0.275 (50% of offering price), subject to stockholder approval.
-
Placement Agent Terms
Aegis Capital received a 7% cash fee plus a 1% non-accountable expense allowance (8% total on ~$6M = ~$480K), plus a 30-month right of first refusal on future financings.
Analysis · SBFM · Life Sciences
A $6 million best-efforts unit offering at $0.55 per unit has been closed by Sunshine Biopharma, issuing 10.5M common shares plus 21.8M Series D Warrants exercisable at $0.66. If fully exercised, the warrants would add up to 43.6 million shares — more than 10x the 4.3 million currently outstanding. The deal carries a Share Combination Event reset that can drop the exercise price to $0.275 if a reverse split occurs and the VWAP falls below the strike, subject to stockholder approval. Against a backdrop of a pending 1-for-20 reverse split authorization and a stock trading near its 52-week low, this financing extends the runway but creates massive potential dilution. The company also granted Aegis Capital a 30-month right of first refusal on future financings and agreed to 90-day lock-ups and a standstill.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.33 to $24.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.